Evidence-based pharmacotherapy of treatment-resistant unipolar depression
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Treatment resistance to the antidepressive pharmacotherapy represents one of the most important clinical challenges in the pharmacological management of unipolar depression. In this review, we aimed to summarise the evidence for various pharmacological treatment options in therapy-resistant unipolar depression derived from clinical trials, systematic reviews, meta-analyses and treatment guidelines. The first measure in case of insufficient response to the initial antidepressant monotherapy contains the debarment of 'pseudo-resistance', potentially caused by inadequate dose and treatment duration of the antidepressant, insufficient plasma levels, non-compliance of the patient regarding medication intake or relevant psychiatric and/or somatic comorbidities. Applying a dose escalation of the current antidepressant cannot be generally recommended as evidence-based treatment option and the efficacy depends on the class of antidepressants. There is no compelling evidence for a switch to another, new antidepressant compound after insufficient response to a previous antidepressant. The combination of two antidepressants should be preferentially established with antidepressants characterised by different mechanisms of action (e.g. reuptake inhibitors together with presynaptic autoreceptor inhibitors). At present, the most convincing body of evidence exists for the augmentation of antidepressants with second-generation antipsychotic drugs and lithium. Hence, both strategies are consistently advised by treatment guidelines as pharmacological first-line strategy in treatment-resistant depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“In the STAR D study, a combination of citalopram with bupropion in patients after a treatment failure with citalopram monotherapy leads to a remission rate of 29.7% (Trivedi et al. 2006a).”
BackgroundInfluentialThe size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 2×
“In the STAR D study, a combination of citalopram with bupropion in patients after a treatment failure with citalopram monotherapy leads to a remission rate of 29.7% (Trivedi et al. 2006a).”
BackgroundInfluentialLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 2×
“…especially patients with a high risk for suicidal behaviour can benefit from adjunctive lithium as the suicide rate under lithium was significantly reduced in a large number of RCTs and observational studies (Kessing et al. 2005; Cipriani et al. 2013; Rombold et al. 2014; Otuyelu et al. 2015).”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 23×
“…guidelines of the international psychiatric societies, an increase of the antidepressant dose above the officially approved dose range (dose escalation) cannot be recommended as general treatment option for the management of treatment-resistant MDD (NICE 2009; APA 2010; Bauer et al. 2013b).”
BackgroundMethodResultInfluentialSouery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 4×
“Factors contributing to treatment resistance Souery et al. (2007) analysed 702 MDD patients participating in a large multicenter study of the European Group for the Study of Resistant Depression and revealed the following clinical factors that were associated with treatment resistance (defined as…”
BackgroundInfluentialSelf-citationMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“These findings are consistent with the [11C]DASB positron emission tomography study of Meyer et al. (2004) investigating the SERT occupancy of SSRIs/venlafaxine whereupon SERT occupancy of 80% occurs already at the minimum therapeutic doses.”
Result
Cited by
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationBartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“2018) representing an essential therapeutic fundament as it is known from other diseases such as arterial hypertension (Kranz and Kasper 2019), up to 60% of MDD patients do not sufficiently respond to an initial antidepressant treatment (Souery et al. 1999, 2006; Kasper 2014; Dold and Kasper 2017).”
BackgroundSelf-citationKautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12959 · Cited by 148
“Based on these shortcomings, research focused on predictive signatures of treatment resistant depression (TRD) for several decades (4, 5).”
BackgroundSelf-citationDold, M., Bartova, L., Souery, D., Mendlewicz, J., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., & Kasper, S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.020 · Cited by 131
Self-citationvan Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
“Clinical reviews suggest a prevailing inclination to manage TRD (solely) by pharmacotherapy or other somatic treatments while scarcely mentioning studies into psychotherapy for TRD with little or no discussion of the findings and prospects (e.g. Carvalho et al., 2014; Dold and Kasper, 2016).”
Background
Metadata
- Authors
- Dold, M., & Kasper, S.
- Venue
- International Journal of Psychiatry in Clinical Practice
- Publisher
- Informa UK Limited
- Published
- 2016-11-16
- Volume
- 21
- Issue
- 1
- Pages
- 13-23
- ISSN
- 1365-1501 (ISSN-L)
- 1471-1788
- OpenAlex
- W2554788508
- Cited by
- 118
- References
- 23
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-based pharmacotherapy of treatment-resistant unipolar depression. https://app.cochat.ai/papers/10.1080/13651501.2016.1248852
- The paper
- Dold, M., & Kasper, S. (2017). Evidence-based pharmacotherapy of treatment-resistant unipolar depression. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651501.2016.1248852
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.